These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 24102425)

  • 1. Requirement for safety monitoring for approved multiple sclerosis therapies: an overview.
    Rommer PS; Zettl UK; Kieseier B; Hartung HP; Menge T; Frohman E; Greenberg BM; Hemmer B; Stüve O
    Clin Exp Immunol; 2014 Mar; 175(3):397-407. PubMed ID: 24102425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis.
    English C; Aloi JJ
    Clin Ther; 2015 Apr; 37(4):691-715. PubMed ID: 25846320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Current immunotherapy of multiple sclerosis].
    Paul F; Ruprecht K
    Nervenarzt; 2015 Aug; 86(8):1031-42; quiz 1043-4. PubMed ID: 26253589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patients.
    Rommer PS; Zettl UK
    Expert Opin Pharmacother; 2018 Apr; 19(5):483-498. PubMed ID: 29528247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunological Aspects of Approved MS Therapeutics.
    Rommer PS; Milo R; Han MH; Satyanarayan S; Sellner J; Hauer L; Illes Z; Warnke C; Laurent S; Weber MS; Zhang Y; Stuve O
    Front Immunol; 2019; 10():1564. PubMed ID: 31354720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drugs for multiple sclerosis.
    Med Lett Drugs Ther; 2021 Mar; 63(1620):42-48. PubMed ID: 33976089
    [No Abstract]   [Full Text] [Related]  

  • 7. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Agents for Relapsing Forms of Multiple Sclerosis.
    Straus Farber R; Harel A; Lublin F
    Annu Rev Med; 2016; 67():309-21. PubMed ID: 26394285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety concerns and risk management of multiple sclerosis therapies.
    Soelberg Sorensen P
    Acta Neurol Scand; 2017 Sep; 136(3):168-186. PubMed ID: 27891572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.
    Johnston J; So TY
    Drugs; 2012 Jun; 72(9):1195-211. PubMed ID: 22642799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Established and novel disease-modifying treatments in multiple sclerosis.
    Cross AH; Naismith RT
    J Intern Med; 2014 Apr; 275(4):350-63. PubMed ID: 24444048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fertility, pregnancy and childbirth in patients with multiple sclerosis: impact of disease-modifying drugs.
    Amato MP; Portaccio E
    CNS Drugs; 2015 Mar; 29(3):207-20. PubMed ID: 25773609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pregnancy and Family Planning in Multiple Sclerosis.
    Langer-Gould AM
    Continuum (Minneap Minn); 2019 Jun; 25(3):773-792. PubMed ID: 31162316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune therapy of multiple sclerosis--future strategies.
    Meuth SG; Göbel K; Wiendl H
    Curr Pharm Des; 2012; 18(29):4489-97. PubMed ID: 22612746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on disease-modifying therapies for multiple sclerosis.
    Vargas DL; Tyor WR
    J Investig Med; 2017 Jun; 65(5):883-891. PubMed ID: 28130412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current and future therapies targeting the immune system in multiple sclerosis.
    Loleit V; Biberacher V; Hemmer B
    Curr Pharm Biotechnol; 2014; 15(3):276-96. PubMed ID: 24938888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulating acute neuroinflammation in intracerebral hemorrhage: the potential promise of currently approved medications for multiple sclerosis.
    Napier J; Rose L; Adeoye O; Hooker E; Walsh KB
    Immunopharmacol Immunotoxicol; 2019 Feb; 41(1):7-15. PubMed ID: 30702002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease-modifying agents in multiple sclerosis.
    O'Connor PW; Oh J
    Handb Clin Neurol; 2014; 122():465-501. PubMed ID: 24507532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.